NIH-funded 'systems biology' project aims to solve TB conundrum
This article was originally published in Scrip
Executive Summary
With the effectiveness unpredictable of the current vaccine used to protect against tuberculosis – which is thought to have infected about a third of the world's population, although most of those cases are latent – and the therapies to treat the infection considered toxic, difficult to take and growing increasingly resistant, it's critical scientists gain a better understanding of the disease, said Dr David Sherman, a professor at Seattle Biomedical Research Institute.